EichorEICHOR
Condition: Egfr Positive Solid Tumors Synced from ClinicalTrials.gov · August 04, 2026

Recruiting studies: Egfr Positive Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06824155Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07617805Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metast
Phase 1 · 4 location(s) · Vir Biotechnology, Inc. · NCT06960395HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05341492A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06947811ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 · 5 location(s) · Changchun Intellicrown Pharmaceutical Co. LTD · NCT04412616Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07712029
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.